2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise
The long-term thesis for Viatris (NASDAQ: VTRS) rests on its drug pipeline, researching and developing generic copies of medicines that are off-patent, with the goal of getting regulators to agree that its generics are comparable to the branded drugs they seek to emulate. Its complex injectable generics, like Glucagon for hypoglycemic disorder, will be among the biggest growth segments, along with its new ophthalmology portfolio; each segment is expected to be worth more than $1 billion in annual revenue before the end of the decade.